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Abstract
Purpose This dedicated QTc study was designed to
evaluate the effect of the mammalian target of rapamycin
inhibitor, ridaforolimus, on the QTc interval in patients
with advanced malignancies.
Methods We conducted a fixed-sequence, single-blind,
placebo-controlled study. Patients (n = 23) received placebo
on day 1 and a single 100-mg oral dose of ridaforolimus on
day 2 in the fasted state. Holter electrocardiogram (ECG)
monitoring was performed for 24 h after each treatment, and
blood ridaforolimus concentrations were measured for 24 h
after dosing. The ECGs were interpreted in a blinded fashion,
and the QT interval was corrected using Fridericia’s formula
(QTcF). After a washout of at least 5 days, 22 patients went
on to receive a therapeutic regimen of ridaforolimus (40 mg
orally once daily for 5 days per week).
Results The upper limit of the two-sided 90 % confidence
interval for the placebo-adjusted mean change from base-
line in QTcF was \10 ms at each time point. No patient
had a QTcF change from baseline[30 ms or QTcF interval
[480 ms. Geometric mean exposure to ridaforolimus after
the single 100-mg dose was comparable to previous
experience with the therapeutic regimen. There appeared to
be no clear relationship between individual QTcF change
from baseline and ridaforolimus blood concentrations. Ri-
daforolimus was generally well tolerated, with adverse
events consistent with prior studies.
Conclusions Administration of the single 100-mg dose of
ridaforolimus did not cause a clinically meaningful pro-
longation of QTcF, suggesting that patients treated with
ridaforolimus have a low likelihood of delayed ventricular
repolarization.
Keywords Ridaforolimus  mTOR inhibitor  QTc
interval  Safety
Introduction
Ridaforolimus (AP23573, MK-8669) is a specific inhibitor
of the mammalian target of rapamycin (mTOR), a serine/
threonine kinase that has a key role in integrating intra-
cellular signals necessary for cell growth, metabolism, and
survival [6, 15]. The activity of mTOR is normally regu-
lated by receptor tyrosine kinases that activate the phos-
phatidylinositol-3-kinase (PI3K)/Akt pathway [2, 5].
Intracellular signaling in the PI3K/Akt pathway is dys-
regulated in many malignancies, usually through gene
mutation or overexpression of key pathway components or
regulatory factors, which leads to increased mTOR activity
[2, 24]. As a result, mTOR represents an attractive thera-
peutic target in cancer.
Preclinical studies have shown that ridaforolimus has
antiproliferative activity against a broad range of human
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tumor cell lines in vitro and in tumor xenograft models in
vivo [21]. Ridaforolimus has also displayed promising
activity in phase 1 and phase 2 clinical trials in patients
with advanced sarcoma and other malignancies [11, 17, 20,
22]. In the recently completed phase 3 Sarcoma mUlti-
Center Clinical Evaluation of the Efficacy of riDaforolimus
(SUCCEED) trial, maintenance therapy with ridaforolimus
administered at a dose of 40 mg orally once daily for 5
consecutive days every week significantly improved pro-
gression-free survival compared with placebo, in advanced
sarcoma patients who achieved clinical benefit (complete
response, partial response, or stable disease) from prior
cytotoxic chemotherapy [4].
Assessment of the potential for corrected QT interval
(QTc) prolongation is an essential component of new drug
development that was prompted by deaths attributed to
cardiac arrhythmias with certain drugs such as terfenadine
and cisapride [7, 23]. The International Conference on
Harmonisation (ICH) formulated the E14 guidance docu-
ment, endorsed by the US Food and Drug Administration,
which specifies that a dedicated QTc study should be
performed for all new drugs in order to evaluate the risk of
QTc prolongation as a biomarker for ventricular tachy-
cardias, especially torsade de pointes [3, 7, 9]. Electro-
cardiogram (ECG) monitoring during phase 1 and phase 2
clinical trials of ridaforolimus did not identify a risk of QTc
prolongation. However, these clinical studies are generally
considered not to accurately determine the true risk of QTc
prolongation with ridaforolimus because ECG measure-
ments were not scheduled to coincide with clinically rel-
evant pharmacokinetic time points (i.e., the time of
maximum ridaforolimus blood concentrations) and the
doses were not sufficient for evaluating whether ridafo-
rolimus affects QTc.
The present QTc study was specifically designed to
evaluate the effect of a single 100-mg oral dose of ridaf-
orolimus on the QTc interval in advanced cancer patients.
This study was developed using the recommendations in
the ICH E14. Conducting this study in cancer patients
placed some notable restrictions on the study design;
however, many of the recommended critical ICH compo-
nents were incorporated, resulting in a dedicated, robust
study design evaluating the potential effect of an anticancer
agent (not amenable for study in the healthy volunteer
population) on ventricular repolarization [19].
Methods
Study design
This 2-part, phase 1 study was conducted at 2 US cen-
ters (ClinicalTrials.gov identifier: NCT00874731; http://
clinicaltrials.gov/ct2/show/NCT00874731; Protocol 037).
Part 1 had a fixed-sequence, single-blind, placebo-con-
trolled design consisting of 2 days of intensive ECG
monitoring for QTc assessment. Patients received a single
oral dose of placebo on day 1 and a single 100-mg oral
dose of ridaforolimus on day 2 while sequestered at the
investigational site. During this part of the study, treatment
was administered in a fasted state, with fasting continued
until 4 h postdose and water restricted for 1 h before and
after dosing. Because the study population had advanced
malignancies that were not amenable to standard anticancer
therapy, patients were offered the opportunity to receive
ridaforolimus in a standard therapeutic regimen after
completing the QTc evaluation. The optional part 2 of the
study had an open-label design, with clinic visits scheduled
every 28 days; it was separated from part 1 by a washout
period of at least 5 days. Patients received ridaforolimus
40 mg once daily for 5 consecutive days every week until
disease progression, unacceptable toxicity, or withdrawal
from the study. A poststudy assessment was scheduled
approximately 30 days after the last dose of study treat-
ment or before initiation of any new treatment.
The study was conducted in compliance with Good
Clinical Practice standards and regulatory requirements for
ethical committee review, informed consent, and protection
of human subjects participating in biomedical research. All
subjects provided written informed consent before any
study-related procedures were conducted.
Patients
Men and women at least 18 years old were eligible if they
had a histologically or cytologically confirmed metastatic
or locally advanced malignancy that progressed after
standard therapy or for which no standard therapy exists.
There was no limit on the number of prior treatment reg-
imens. Eligible patients had Eastern Cooperative Oncology
Group performance status of 0–2, adequate hematologic,
renal, and hepatic functions, coagulation parameters B1.2
times the upper limit of normal, serum potassium and
magnesium within normal limits, and a life expectancy of
[3 months. Females of childbearing potential agreed to
use 2 approved contraceptive methods from screening until
30 days after the last dose of ridaforolimus; males with a
female partner of childbearing potential also agreed to use
medically acceptable contraception during this time period.
Patients were excluded if they had received chemo-
therapy, radiotherapy, or biological agents within 4 weeks
of the first dose of treatment (6 weeks for monoclonal
antibodies, nitrosoureas, or mitomycin C), had not recov-
ered from adverse events (AEs) due to prior therapy, or
were receiving concurrent anticancer therapy (except
luteinizing hormone–releasing hormone analogs for
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prostate cancer or supportive therapy) or immunosuppres-
sive therapy (except stable doses of corticosteroid
replacement therapy). Patients with specific ECG inter-
vals (PR [0.26 s, QRS C0.12 s, Fridericia-corrected QT
[QTcF] C470 milliseconds (ms), RR [1.2 s, or ventricular
rate\50 beats per minute after sitting quietly for 10 min),
history of risk factors for torsade de pointes (e.g., heart
failure, uncorrected hypokalemia, family history of long
QT syndrome), or a history of sick sinus syndrome, second-
or third-degree atrioventricular block, myocardial infarc-
tion, unstable angina pectoris, or cardiac arrhythmia were
also excluded. Other exclusion criteria were primary cen-
tral nervous system tumor or active brain metastases, newly
diagnosed or poorly controlled diabetes, recent history of
drug or alcohol abuse, human immunodeficiency virus
positive or known history of hepatitis B or C, treatment
with medications that induce or inhibit cytochrome P450
(CYP3A4) within 2 weeks, treatment with medications
known to prolong QTc interval within 4 weeks, active
infection or intravenous (IV) treatment with antimicrobial
agents within 2 weeks, prior high-dose chemotherapy with
stem-cell rescue, blood transfusion within 1 week, or par-
ticipation in a study of an investigational compound or
device within 30 days.
Electrocardiogram assessments
Holter ECG monitoring was performed for 24 h after each
dose in part 1 using a Mortara H12? digital Holter
recorder. Patients rested in a supine position for at least
10 min before and 5 min after each prespecified ECG time
point (predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 h after
dosing). Five ECG recordings were extracted from the
Holter monitor at each of these time points, according to a
prespecified algorithm at a centralized ECG core laboratory
(Quintiles ECG Services; Mumbai, India). The ECGs were
interpreted by cardiologists who were blinded to treatment
allocation, patient, and time of the ECG. The ECG
recordings for a single subject were evaluated by a single
cardiologist reader on the same day. At each time point, the
ECG intervals in the 5 recordings were averaged to reduce
variability and increase precision of the estimate. QT
interval was measured in lead II, with an alternate lead
used if the lead II recordings were of suboptimal quality,
and Fridericia’s correction to the QT interval
(QTcF = QT/RR0.33) was made in order to correct for
heart rate [10].
Pharmacokinetic analysis
Ridaforolimus blood concentrations were determined on
day 2 during the first part of the study. Blood samples
(5 mL) were collected before dosing and at 0.5, 1, 2, 3, 4,
6, 8, 10, and 24 h after dosing. Samples were analyzed for
blood ridaforolimus concentrations by Charles River Lab-
oratories Preclinical Services (Shrewsbury, MA) using a
validated high-performance liquid chromatography/mass
spectrometry/mass spectrometry (HPLC–MS/MS) method
after isolation of the analyte by liquid–liquid extraction
[11]. The lower limit of quantitation for the method was
0.2 ng/mL, with a linear calibration range of 0.2 ng/mL to
400 ng/mL. Pharmacokinetic parameters were determined
by standard methods: maximum blood concentration
(Cmax) and time to maximum concentration (Tmax) were
obtained by inspection of the blood concentration data, and
area under the concentration–time curve from zero to 24 h
(AUC0-24) was calculated using the linear trapezoidal rule
for ascending concentrations and the logarithmic trape-
zoidal rule for descending concentrations. Plasma samples
were collected, but not assayed; this is because ridaforol-
imus disproportionately partitions into red blood cells and
is highly bound to proteins.
Safety assessments
Safety was assessed through clinical and laboratory eval-
uations while patients were sequestered at the investiga-
tional site during part 1, at clinic visits every 28 days
during part 2, and at the poststudy visit. Vital signs were
measured after patients rested in a semirecumbent position
for 10 min predose, at 4 and 24 h after dosing in part 1, and
at each subsequent clinic visit. Standard 12-lead ECG
recordings were also obtained, including 8 h postdose in
part 1. Cardiac troponin I levels were determined as part of
the laboratory assessment in part 1 because preclinical
safety studies had demonstrated a small risk of cardiac
myonecrosis in primates. All AEs were assessed in terms of
relationship to study treatment, and their intensity was
graded by the investigator using the National Cancer
Institute’s Common Terminology Criteria for Adverse
Events (CTCAE version 3.0). Clinical AEs were classified
using the Medical Dictionary for Regulatory Activities
(MedDRA version 11.0)–preferred terms by system organ
class.
Statistical analysis
The primary end point of the study was the placebo-
corrected change in QTcF from baseline, with the baseline
value for each patient defined as the average of 5 replicate
QTcF measurements made predose. The change from
baseline in QTcF was analyzed using a repeated-measures
mixed model, with treatment, time, and treatment-by-time
interaction as fixed factors and subject as the random fac-
tor. The mean of the difference in QTcF change from
baseline between ridaforolimus and placebo and its upper
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limit of the two-sided 90 % confidence intervals (CIs),
equivalent to an upper one-sided 95 % CI limit, were
calculated at each prespecified time point using the
appropriate error term from the model and referencing a
t-distribution. The incidence of QTcF values B450, [450,
[480, and [500 ms and changes from baseline in QTcF
\30, C30, and C60 ms were summarized by treatment and
time point. Changes from baseline in QTcF versus ridafo-
rolimus blood concentration were evaluated graphically
using individual patient data. Since there was no clinically
meaningful QTc prolongation based on the formal statis-
tical analysis of placebo-corrected changes from baseline,
no formal pharmacokinetic/QTc modeling was performed.
Safety and pharmacokinetic parameters were tabulated and
summarized using descriptive statistics.
Results
Patient disposition, demographics, and baseline
characteristics
Twenty-three patients were enrolled in the study: 15
women and 8 men. The mean age was 54.4 years, and most
patients were white (95.7 %) (Table 1). The most common
malignancies were bone and soft tissue sarcoma (39.1 %)
and colon cancer (21.7 %). The cohort was heavily pre-
treated: all patients had received at least 2 lines of prior
chemotherapy, with a mean of 4.4 prior regimens. Most
patients (91.3 %) received concomitant medications during
part 1 of the study—most frequently analgesics (60.9 %),
mineral supplements (39.1 %), and vitamins (39.1 %). All
medications known to affect the CYP3A4 metabolism of
ridaforolimus were discontinued before the study (except
for one patient who continued to take pioglitazone).
All patients (N = 23) who were enrolled in the study
received placebo on day 1. Following placebo treatment,
QTcF data were available for 22 patients; one patient did
not have QTcF data since the QT interval could not be
measured in one patient due to nonspecific T wave chan-
ges. One patient discontinued due to disease progression
after receiving placebo on day 1 of part 1. Twenty-two
patients received ridaforolimus 100 mg on day 2 of part 1
and subsequently entered part 2 of the study. After ridaf-
orolimus treatment on day 2, QTcF data were available for
20 patients. One patient could not be evaluated (the same
patient previously excluded from day 1 QTcF data). The
other patient took a protocol-violating medication
(CYP3A4 inducer pioglitazone); however, for day 1 (pla-
cebo day), it was determined that this medication did not
preclude the patient’s Holter data from being included,
since ridaforolimus was not administered on day 1. Phar-
macokinetic data were available for 21 patients, as 2
patients were not included (the one patient who discon-
tinued and the other patient who took a protocol-violating
medication).
Electrocardiogram and pharmacokinetic effects
The average blood ridaforolimus concentration profile rose
to peak levels over 4–6 h postdose and then decreased in an
approximately biphasic manner until 24 h after oral
administration of a single 100-mg dose (Fig. 1a). The
geometric mean Cmax of ridaforolimus was 186 ng/mL
(95 % CI: 159, 218), and the median Tmax was 4.2 h after
dosing (Table 2). Administration of the single 100-mg dose
of ridaforolimus did not prolong the QTcF interval, inas-
much as the upper limit of the 90 % CI for the placebo-
adjusted mean change from baseline difference (between
ridaforolimus and placebo) in QTcF was \10 ms at each
time point (Fig. 1b; Online Resource 1). The largest pla-
cebo-corrected change from baseline occurred 10 h after
dosing, with a mean difference of 3.89 ms (90 % CI: 0.60,
7.17) in QTcF change from baseline after ridaforolimus
versus placebo administration. For all other time points, the
90 % CI included zero. Similar results were obtained in an
exploratory analysis, in which the mean change from
baseline in QTcF between ridaforolimus and placebo and
its 90 % CIs were computed based on paired t tests.
In the categorical analyses, none of the patients had an
observed QTcF change from baseline [30 ms, and only













Cancer type, n (%)
Bone and soft tissue sarcoma 9 (39.1)
Breast 3 (13.0)
Colon 5 (21.7)
Other (e.g., cervical, esophageal, non–small cell
lung, rectal, ureteral, and uterine sarcoma)
6 (26.1)
Prior regimens
Mean, n (SD) 4.4 (2.1)
Range 2.0–9.0
SD standard deviation
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one patient experienced a QTc interval [450 ms. This
patient had day 1 QTcF values of 459.8, 453.8, 454.6,
450.4, and 451.2 ms at predose, 0.5 h after placebo, 1 h
after placebo, 2 h after placebo, and 3 h after placebo,
respectively, and values of 453.6 and 456.4 ms at 1 and 3 h
after ridaforolimus on day 2, respectively. For the study
cohort, no clear relationship was evident between the
individual QTcF changes from baseline and ridaforolimus
blood concentrations (Fig. 2). The appropriateness of using
QTcF was evaluated graphically and by simple linear
regression of QTcF versus RR interval using the placebo
data: the estimated slope from the regression was 0.0060
(95 % CI: -0.0069, 0.0190), suggesting that Fridericia’s
correction method was adequate.
Exploratory analyses were conducted on other ECG
parameters. Mean PR and QRS intervals remained essen-
tially unchanged during the 24-h periods after placebo and
ridaforolimus; the largest placebo-corrected mean changes
from baseline in PR and QRS intervals were 5.29 ms
(90 % CI: 1.83, 8.74) and 3.47 ms (90 % CI: 2.13, 4.80),
respectively, both seen at 24 h after dosing. In contrast, the
mean RR interval varied during the 24-h dosing interval on
days 1 and 2, with placebo-corrected values being negative at
all time points; the largest placebo-corrected mean change
from baseline in RR interval was -64.16 ms (90 % CI:
-97.52, -30.80), which was observed at 24 h after dosing.
Safety and tolerability
All 23 patients enrolled were evaluated for safety in part 1
after receiving placebo; the 22 patients who received ri-
daforolimus in part 1 of the study and subsequently entered
part 2 were included in the safety evaluation. In part 1, a
single 100-mg dose of ridaforolimus was generally well
tolerated by patients with advanced cancer; no patient
discontinued treatment due to an AE. Eleven patients
(47.8 %) had AEs after placebo, and 18 patients (81.8 %)
had AEs after the 100-mg dose of ridaforolimus. The most
common AEs occurring in at least 15 % of patients were
fatigue (27.3 %), thrombocytopenia (22.7 %), leukopenia
(18.2 %), lymphopenia (18.2 %), and stomatitis (18.2 %).
Although treatment was not blinded, 12 patients (54.5 %)
had treatment-related AEs according to the investigator,
most frequently thrombocytopenia and stomatitis; all
treatment-related AEs were grade 1 or 2 (Table 3). Cardiac
troponin I values remained within normal limits
(0–0.78 ng/mL) in all patients.
In part 2 of the study, patients received a once-daily,
40-mg dose of ridaforolimus for 5 days every week for a
median of 4.0 weeks (range 0.2–24.0 weeks; mean ±
standard deviation: 6.7 ± 5.8 weeks). Ridaforolimus
administered in part 2 was also generally well tolerated.
Adverse events regardless of causality were experienced by
21 patients (95.5 %); the most common were mucosal
inflammation or mucositis (40.9 %), fatigue (40.9 %),
diarrhea (36.4 %), stomatitis (27.3 %), and decreased
appetite (22.7 %). Most AEs were grade 1 or 2, did not
Fig. 1 a Arithmetic mean blood concentration–time profile after oral
administration of single 100-mg dose of ridaforolimus to patients with
advanced cancer (n = 21). One patient was excluded from average
blood concentration profile due to a protocol violation. b Placebo-
adjusted means and 90 % confidence intervals (CIs) for change from
baseline of Fridericia-corrected QTc (QTcF) intervals. The upper
limit of the 90 % CI for the placebo-adjusted mean change from
baseline in QTcF was \10 ms at each time point, indicating that
ridaforolimus did not prolong the QTcF interval
Table 2 Summary statistics for ridaforolimus blood pharmacokinetic
parameters after administration of a single 100-mg oral dose of ri-
daforolimus to advanced cancer patients
Pharmacokinetic parameter Geometric mean (95 % CI) (n = 21)
AUC0-24 (hng/mL) 1,875 (1,623, 2,167)
Cmax (ng/mL) 186 (159, 218)
Tmax (h)
a 4.2 (2.2, 10.0)
CI confidence interval, AUC0-24 area under the concentration–time
curve from zero to 24 h, Cmax maximum concentration, Tmax time to
maximum concentration
a Median (minimum, maximum) for Tmax
Cancer Chemother Pharmacol (2012) 70:567–574 571
123
require special attention, and were manageable with tem-
porary dose reduction or supportive care measures. Treat-
ment-related AEs were reported for 17 patients (77.3 %),
most frequently mucosal inflammation or mucositis
(36.4 %), stomatitis (27.3 %), fatigue (27.3 %), diarrhea
(27.3 %), and thrombocytopenia (18.2 %). Thrombocyto-
penia and fatigue (each in 2 patients; 9.1 %) were the most
common grade 3 events; no grade 4 events were reported.
Five patients (22.7 %) required dose modifications until
resolution or improvement of treatment-related AEs.
Serious AEs were reported in 8 patients (36.4 %),
including 2 (9.1 %) with events considered related to
treatment (viral bronchitis and pneumonitis). Three patients
discontinued due to AEs: one patient discontinued due to
treatment-related mucositis and 2 patients discontinued due
to AEs unrelated to study treatment (elevated bilirubin and
pneumonia). Two patients died during the course of the
study due to disease progression. Laboratory safety testing
revealed some clinically significant laboratory abnormali-
ties; most notable was elevated uric acid levels experienced
by 6 patients (26.1 %). Elevated uric acid had no physio-
logic consequences, and therefore, these were considered
grade 1 events according to CTCAE criteria. Four patients
(17.4 %) had elevated glucose, which is known to be
associated with mTOR inhibition. Other safety assess-
ments, including vital signs, physical examinations, and
12-lead ECGs, did not show clinically meaningful findings
as a function of treatment.
Discussion
The results of this dedicated QTc study demonstrate that
administration of a single 100-mg oral dose of




administration of single 100-mg
dose of ridaforolimus to patients








adverse events occurring in over
5 % of patients and all grade 3
events reported in any treatment
group
a None of the patients who
received placebo treatment
(n = 23) experienced a
treatment-related adverse event;
no patient experienced events
greater than grade 3 in any
treatment group
Adverse event, n (%)a Single 100-mg dose oral ridaforolimus
(n = 22)
40-mg dose, once daily for 5 days/week
(n = 22)
All grades Grade 3 All grades Grade 3
Leukopenia 3 (13.6) 0 1 (4.5) 0
Lymphopenia 3 (13.6) 0 2 (9.1) 1 (4.5)
Neutropenia 2 (9.1) 0 1 (4.5) 0
Thrombocytopenia 5 (22.7) 0 4 (18.2) 2 (9.1)
Diarrhea 0 0 6 (27.3) 0
Nausea 2 (9.1) 0 2 (9.1) 0
Stomatitis 4 (18.2) 0 6 (27.3) 0
Fatigue 1 (4.5) 0 6 (27.3) 2 (9.1)
Mucosal inflammation 0 0 8 (36.4) 1 (4.5)
Decreased appetite 1 (4.5) 0 3 (13.6) 0
Dysgeusia 1 (4.5) 0 2 (9.1) 0
Acne 0 0 2 (9.1) 0
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ridaforolimus does not prolong the QTcF interval in patients
with advanced malignancies. The upper bound of the 90 %
CI of the placebo-corrected mean QTcF change from base-
line was \10 ms at every time point measured during the
24-h evaluation period. The categorical analyses of QTcF
and change from baseline in QTcF further support the con-
clusion that ridaforolimus does not prolong QTcF. Only one
patient had a QTcF interval[450 ms, which was observed
after both placebo and ridaforolimus; no patient had a
QTcF [480 ms or change from baseline [30 ms. Whole-
blood pharmacokinetics of ridaforolimus were also deter-
mined over the 24-h period after dosing. The timing of blood
collection coincided with the timing of ECG measurement in
order to evaluate whether there was a concentration–time
relationship, as recommended in E14 guidelines [13]. Indi-
vidual QTcF changes from baseline versus ridaforolimus
blood concentrations revealed no clear concentration–time
relationship. Moreover, maximum exposure to ridaforoli-
mus was observed 4–6 h after administration; at these time
points, the placebo-corrected changes from baseline in QTcF
were 1.18 ms (90 % CI: -2.10, 4.47) and 2.49 ms (90 % CI:
-0.79, 5.78), respectively. These findings suggest that ri-
daforolimus is not likely to cause a clinically meaningful
prolongation of the QTc interval in patients with cancer.
Since this study evaluated ridaforolimus in an advanced
cancer population, its design was modified from the thor-
ough QT/QTc study recommended in E14 guidance. A
positive control that prolongs QTc was not included due to
the overall poor health of the study population. A ran-
domized crossover design was not used because the long
half-life of ridaforolimus (*50 h) would have necessitated
a long washout period, which would not have been ethical
or acceptable for this population of advanced cancer
patients. However, the study design did incorporate many
key E14 recommendations, including the use of replicate
ECG recordings to reduce variability, use of a centralized
core laboratory blinded to time and treatment to reduce
bias and variability, use of a placebo, and measurement of
blood ridaforolimus concentrations at times of the ECG
assessments to evaluate potential pharmacokinetic–phar-
macodynamic relationships. A similar study design was
used previously to evaluate the effect of vorinostat on QTc
in advanced cancer patients [19].
The single 100-mg oral dose used in this study was
selected for several reasons. First, this single suprathera-
peutic dose provided the highest attainable whole-blood
ridaforolimus Cmax, given the toxicity limitations associ-
ated with administration of multiple supratherapeutic
doses. The therapeutic dose of 40-mg oral ridaforolimus
administered once daily for 5 consecutive days every week
is the maximum tolerated dose; the onset of dose-limiting
toxicity occurs within the first week at higher doses [17].
Second, the 100-mg dose is the highest single oral dose that
has been administered to patients and was predicted by
pharmacokinetic modeling to provide exposure at least
comparable with that achieved with the therapeutic dose.
Similar to other rapamycin analogs [12, 14, 16], ridafo-
rolimus exhibits saturable binding to erythrocytes, which
may be an important contributor to the drug’s nonlinear
whole-blood pharmacokinetics, with less than proportional
increases in whole-blood exposure following oral or IV
administration [8, 17, 18]. Following the single 100-mg
dose in the present study, the geometric mean whole-blood
AUC0-24 was 1,875 hng/mL and Cmax was 186 ng/mL.
These values approximate the steady-state exposures to
ridaforolimus achieved with the therapeutic dose of 40 mg
once daily for 5 days every week, but are not considered
supratherapeutic. Third, higher single doses were not
administered because they would not have provided pro-
portionally higher exposure given the nonlinear blood
pharmacokinetics of ridaforolimus.
Adverse events observed in this study were consistent
with the known safety profile of ridaforolimus in other
clinical studies, as well as the safety profiles of other
mTOR inhibitors. The most common treatment-related
AEs included thrombocytopenia, stomatitis, mucosal
inflammation, fatigue, and diarrhea. To date, preclinical
studies with ridaforolimus, as well as the safety database
for ridaforolimus in cancer patients, have shown no signal
for QTc prolongation. Results from this study are consis-
tent with a preclinical risk assessment made on the basis of
current ICH S7A and S7B guidelines [1]. The hERG
channel was only minimally inhibited at the highest ri-
daforolimus concentration tested (5 % inhibition at
50 lM). This concentration for minimal hERG inhibition is
more than 100 times higher than the Cmax measured in
whole blood following the 100-mg dose or 40-mg thera-
peutic regimen. The present data with a single 100-mg oral
dose indicate that ridaforolimus has a low likelihood of
causing delayed ventricular repolarization. Because expo-
sure to ridaforolimus after this single dose approximates
the exposure at steady-state with the 40-mg therapeutic
regimen, treatment with ridaforolimus is not likely to cause
a clinically meaningful prolongation of the QTc interval in
patients with cancer.
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